ClinicalTrials.gg
CompletedNCT03469453BIPWorryUpdated May 6, 2019

Internet-delivered CBT for Adolescents With GAD

An interventional study of Internet-Delivered Cognitive Behavioral Therapy in Generalized Anxiety Disorder, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-05-06.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
13 Years to 17 Years
Sex
All
01

Study summary

This multiple baseline evaluation aims to test the feasibility and preliminary effectiveness of Internet-delivered cognitive behavioral therapy (ICBT) for adolescents with Generalized Anxiety Disorder (GAD).

Read the detailed description

This pilot study aims to test Internet-delivered Cognitive Behavioral Therapy (ICBT) for adolescents with Generalized Anxiety Disorder (GAD)

The study has a single case research design (multiple baseline) and will include 12 participants with GAD according to a semi structured diagnostic interview.

Participants will be randomized to either two, six or ten weeks baseline measurements prior to starting treatment, and will thus work as their own controls.

Primary outcome measures will be collected at 10 weeks after treatment start. Follow-up assessments will be made three month after treatment.

02

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • GAD
  • Adolescents
  • Internet-delivered Cognitive behavioral therapy
  • ICBT
  • CBT
03

In context

Generalized Anxiety Disorder

146 studies on the registry are indexed under Generalized Anxiety Disorder; 86 are open to participants now.

This study's enrollment of 13 is below the median of 100 across 120 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,146 studies on the registry; 275 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A score on the Penn State Worry Questionnaire for Children (PSWQ-C) of > 30
  • Fulfilling DSM-5 criteria for Generalized Anxiety Disorder
  • No other disorder or symptoms present in need of more urgent treatment
  • Aged between 13 and 17 years
  • Ability to read and write in Swedish
  • A parent or caregiver that is able to participate in the treatment
  • Participants on psychotropic medication must have been on a stable dose for the last 6 weeks prior to baseline assessment
  • No other ongoing psychological treatment for any disorder

Exclusion criteria

Exclusion Criteria:

  • The presence of symptoms suggestive of a current diagnosis of Autistic Spectrum Disorder, Schizophrenia, Bipolar Disorder, Anorexia Nervosa, Bulimia, or Substance Use Disorder
  • Present risk of suicide
  • Present occurrence of domestic violence
  • Completed CBT for any anxiety disorder within the last 6 months (defined as at least 5 sessions of CBT including in vivo exposure sessions)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Internet-delivered CBT

    Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.

    Behavioral: Internet-Delivered Cognitive Behavioral Therapy

Interventions

  • BehavioralInternet-Delivered Cognitive Behavioral Therapy

    Therapist-supported CBT delivered online.

    Also known as: ICBT

06

What researchers measure

Primary outcomes

  1. Brief Penn State Worry Questionnaire for Children

    Self-assessment of excessive worry for individual analysis in multiple baseline evaluation

    Time frame: 10 weeks after baseline

  2. Penn State Worry Questionnaire for Children

    Child and parent version, lower values indicating decrease in worry. Assessments used in group statistical analysis of clinical outcome

    Time frame: 10, 14 and 22 weeks after baseline

Secondary outcomes

  1. Brief Intolerance of Uncertainty Scale

    Child version, lower values indicating decrease in intolerance of uncertainty

    Time frame: 10, 14 and 22 weeks after baseline

  2. Brief Cognitive Avoidance Questionnaire

    Child version, lower values indicating decrease in cognitive avoidance

    Time frame: 10, 14 and 22 weeks after baseline

  3. Negative Problem Orientation Questionnaire, abbreviated

    Child version, lower values indicating decrease in negative problem orientation

    Time frame: 10, 14 and 22 weeks after baseline

  4. Revised Children's Anxiety and Depression Scale

    Child and parent versions, lower values indicating decrease in anxiety and depression

    Time frame: 10, 14 and 22 weeks after baseline

  5. Education, Work and Social Adjustment Scale

    Child and parent versions, , lower values indicating decreased impairment due to worry

    Time frame: 10 and 22 weeks after baseline

  6. Clinical Global Impression - Improvement

    Clinician rated, higher values indicate larger improvement after treatment

    Time frame: 10, 14 and 22 weeks after baseline

  7. Anxiety Disorder Interview Schedule for the Diagnostic and Statistical Manual -IV

    Diagnostic interview

    Time frame: 10, 14 and 22 weeks after baseline

  8. Clinician Severity Rating

    Clinician rated severity with lower values indicating lower level of severity of a disorder

    Time frame: 10, 14 and 22 weeks after baseline

  9. Children's Global Assessment Scale

    Clinician rated global functioning, higher values indicate higher functioning

    Time frame: 10, 14 and 22 weeks after baseline

Other outcomes

  1. Treatment credibility and expectancy scale (child and parent version)

    A 5-item scale, rated from 0-10, with higher scores indicating higher treatment credibility and expectancy.

    Time frame: 10 weeks after baseline

  2. Negative Events Questionnaire (child and parent version)

    The 5-item scale queries negative events during treatment and if the participants attributes the event to the intervention.

    Time frame: 10 weeks after baseline

  3. Client satisfaction questionnaire

    Child- and parent rated treatment satisfaction is rated on an eight items scale,ange 0-3, with higher score indicating higher satisfaction..

    Time frame: 10 weeks after baseline

  4. Internet intervention Patient Adherence Scale

    Clinician rated, 5-item scale ranging from 0-4 with higher scores indicating higher participant adherence to treatment.

    Time frame: 5 and 10 weeks after baseline

07

Study locations

1 site
  • Karolinska Institutet
    Stockholm, 171 77, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Aug 2018, 9 months.

Of 66 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 67. This study's 9 months is below that.

Counting every sponsor, half of 69 studies reached it within 33 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Mar 19, 2018
StartActual
Nov 28, 2017
Primary completionActual
Aug 28, 2018
CompletionActual
Aug 28, 2018
Last update
May 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03469453
Collaborators
Region Stockholm
Responsible party
Eva Serlachius (Associate professor, Karolinska Institutet) — Principal investigator
First posted
Mar 19, 2018
Start date
Nov 28, 2017
Primary completion
Aug 28, 2018
Completion
Aug 28, 2018
Last update
May 6, 2019

Study contacts

Eva Serlachius, MD, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion